Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects
Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) is one of the best breakout stocks to invest in.
Kalvista Pharmaceuticals Inc. (KALV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Tang Capital Management Kevin C. Tang | 5,041,798 | $61,409,100 | +3% | 2.36% |
| 2. | Suvretta Capital Management Aaron Cowen | 4,768,712 | $58,082,912 | -4% | 1.49% |
| 3. | Millennium Management Israel Englander | 2,096,223 | $25,531,996 | +516% | 0.01% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,920,664 | $23,393,688 | 0.11% | |
| 5. | Parkman Healthcare Partners Greg Martinez | 1,735,003 | $21,132,337 | +156% | 2.2% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.42 | 25,000 | $235,500.00 | 5,303,985 | 2025-04-09 | Filing | |
| $9.33 | 61,700 | $575,661.00 | 5,278,985 | 2025-02-13 | Filing | |
| $9.23 | 100,000 | $923,000.00 | 5,217,285 | 2025-02-12 | Filing | |
| $9.18 | 26,703 | $245,133.54 | 5,117,285 | 2025-02-11 | Filing | |
| $9.14 | 4,137 | $37,812.18 | 5,090,582 | 2025-02-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.45 | 3,813 | $51,288.66 | 39,728 | 2025-11-24 | Filing | |
| $13.45 | 4,471 | $60,139.42 | 10,529 | 2025-11-24 | Filing | |
| $13.45 | 4,331 | $58,256.28 | 223,508 | 2025-11-24 | Filing | |
| $13.45 | 5,296 | $71,236.50 | 131,831 | 2025-11-24 | Filing | |
| $13.45 | 10,940 | $147,153.94 | 416,189 | 2025-11-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,728,985 | $81,959,037 | 4.61% | |
| 2. | 5,039,867 | $61,385,580 | 1.84% | |
| 3. | 3,177,587 | $38,703,010 | 0.01% | |
| 4. | 3,126,117 | $38,076,105 | 0% | |
| 5. | 2,501,119 | $30,463,629 | 0% |
News See All
10 Best Breakout Stocks to Invest In
The US stock market is running high, hitting record highs, bolstered in part by continued optimism around artificial intelligence.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to KalVista Pharmaceuticals' 2025 Third Quarter Financial Update and Operating Results Conference Call.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2026 Earnings Call Transcript
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2026 Earnings Call Transcript September 11, 2025KalVista Pharmaceuticals, Inc. misses on earnings expectations.
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista Pharmaceuticals, Inc.
10 Stocks With Huge Catalysts on the Horizon
The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.
16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts.
5 Best Micro Cap Stocks To Invest In
In this piece, we will take a look at the five best micro cap stocks to invest in.
Hedge Funds Are Buying KalVista Pharmaceuticals, Inc. (KALV)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Are Cashing Out Of KalVista Pharmaceuticals, Inc. (KALV)
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).